The earnings call highlighted significant progress in revenue growth, cost management, and strategic partnerships with major companies like Werfen and Hologic. Scientific advancements also promise future potential. However, challenges remain, such as unpredictable revenue and uncertainty in closing additional licensing agreements.

Company Guidance

During the third quarter 2025 earnings call, VolitionRx Limited provided guidance focusing on their strategic efforts and partnerships. The company emphasized the commercialization of their Nu.Q platform, highlighting two significant agreements: a research license and exclusive commercial option rights agreement with Werfen for antiphospholipid syndrome (APS) and a co-marketing and service agreement with Hologic. With an APS market potential of approximately $85 million annually, the partnerships are expected to leverage Volition's unique NETs platform. The company's financial performance showed a 32% increase in revenue compared to the previous year, reaching $0.6 million, while operating expenses decreased by 10%. Additionally, Volition received $1.2 million from a registered direct offering and approximately $6.1 million from a public offering after the quarter's end. The company aims to achieve cash neutrality through licensing deals in human and veterinary spaces and anticipates further growth from these strategic collaborations and ongoing discussions with potential partners.

Revenue Growth

Revenue for the third quarter grew 32% over the same quarter last year, reaching $0.6 million.

Cost Management

Operating expenses for the quarter were down 10% year-on-year and down 18% for the first three quarters.

Partnership with Werfen

VolitionRx signed a research license and exclusive commercial option rights agreement with Werfen for antiphospholipid syndrome (APS), potentially opening a market of approximately $85 million annually.

Partnership with Hologic

A co-marketing and service agreement with Hologic to promote Nu.Q Discover services, leading to the first sale by Hologic.

Scientific Advancements

Significant progress in the Capture-Seq project, potentially a revolutionary new liquid biopsy method for cancer detection.

Cash Flow Improvement

Net cash used in operating activities was $3.6 million for the quarter, down 33% over the same period last year.

VolitionRX (VNRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VNRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 31, 2026	2025 (Q4)	-0.05 / -	-0.06	―	―	―
Nov 13, 2025	2025 (Q3)	-0.04 / -0.05	-0.07	28.57% (+0.02)	―
Aug 14, 2025	2025 (Q2)	-0.05 / -0.06	-0.085	29.41% (+0.03)	―
May 15, 2025	2025 (Q1)	- / -0.06	-0.1	40.00% (+0.04)	―
Mar 31, 2025	2024 (Q4)	-0.04 / -0.06	-0.1	40.00% (+0.04)	―
Nov 14, 2024	2024 (Q3)	-0.07 / -0.07	-0.11	36.36% (+0.04)	―
Aug 14, 2024	2024 (Q2)	-0.09 / -0.09	-0.14	39.29% (+0.06)	―
May 13, 2024	2024 (Q1)	-0.10 / -0.10	-0.15	33.33% (+0.05)	―
Mar 25, 2024	2023 (Q4)	-0.10 / -0.10	-0.13	23.08% (+0.03)	―
Nov 14, 2023	2023 (Q3)	-0.13 / -0.11	-0.14	21.43% (+0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VNRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 13, 2025	$0.35	$0.33	-5.71%
Aug 14, 2025	$0.64	$0.69	+7.81%
May 15, 2025	$0.45	$0.43	-4.44%
Mar 31, 2025	$0.57	$0.52	-8.77%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does VolitionRX Ltd. (VNRX) report earnings?

VolitionRX Ltd. (VNRX) is schdueled to report earning on Mar 31, 2026, After Close (Confirmed).

What is VolitionRX Ltd. (VNRX) earnings time?

VolitionRX Ltd. (VNRX) earnings time is at Mar 31, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VNRX EPS forecast?

VNRX EPS forecast for the fiscal quarter 2025 (Q4) is -0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing